Nice strong finish today above $24 after staying below $23 majority of the day!
Nothing wrong folks. The entire sector was down. We should probably start heading back up tomorrow as EXEL is one of the top Mid size Bio and there's a lot of interest in the company by big pharma. We have some major catalyst events coming in the second half of the year starting with probably another stellar qtr (showing profits). Be smart and add if you're able to as that's what smart (BIG) money is doing on days like today! Back to $25 plus and hopfefully $26 before end of week!
First Patient Receives Dose in Trial for Combo of Cabometyx, Tecentriq
The Phase 1 clinical trial assessing Cabometyx, Tecentriq combo in advanced urothelial carcinoma or renal cell carcinoma has dosed its first participant.
Debt free!!! This should now move on pass $26 per share.
Gilead knocking? $50/share?
Probably finish green today, no one wants to be out of Exel when news hits, any news: NCCN, HCC, Genentech arbitration, sNDS,trial surprises or buyout, lots going on here.
is stock still a buy or wait for a pull back?
Assault on $26 today! Momo continues for EXEL
Looks like a breather today. I am fine with new base around 24. This base will allow increase to 27-28 before Q2 earnings call.
I suggest for every Longs, if anyone whose brokerage account is marginable, to avoid Short Sellers can borrow your shares to sell short, please put a sell order your owning shares at very high price such as $50 a share. That's way, your brokerage account does not have shares available for short
cup and handle pattern setting up nicely
The SEC filings explain last friday....... 24.5 Millions shares for "2017 EQUITY INCENTIVE PLAN"
Hello to $25 PPS!!🍾🍾 to all longs!!
when cabo gets bought out im goin to cabo
$25 !!! Hear we go. Marching up? That's good. It's a wonderful Monday.
I believe the HCC data is leaking. HF always finds out and make money with this kind of privileged information!
Okay sports fans, From a very experienced biotech investor of multiple decades and dozens of biotech investments, it’s show me the money. More specifically it’s show me the revenue. You can see here from this chart the high correlation between market cap and revenue. In billions MCap Revenue AMGN 134 22.6 CELG 97 13.2 BIIB 60 11.4 REGN 41 5.5 VRTX 34 2.2 ALXN 28 3.4 INCY 28 1.4 BMRN 17 1.3 SGEN 9 0.5 IONS 7 0.37 EXEL 7 0.36 KITE 5 0.2
So here is the point. If you expect cabo to be approved in first line RCC, with Sutent revenues now near a billion and if any of the combination studies too numerous to mention come to fruition, I don’t think an expectation of EXEL total revenues including cobi of 1.5billion to be outlandish. Therefore from the chart, I also think a market cap of 20 billion is very plausible. A 20 billion market cap puts EXEL around 70. (go Hairy! Kaboom!) So you can root for a short term bump for a buyout if you want. A very generous 35-40 percent market premium for a buyout only puts you at 33 to 34 dollars. Personally I’d rather wait a little longer for 70 and have a chance for 100 plus. I am long EXEL. I composed this myself and did it pretty fast so there could be errors in market cap and revenue estimates which are approximate. However, I think it’s accurate enough to draw the logical conclusions. I am not receiving any compensation for this and have no relationship with the company other than as a stockholder.
Next resistance 25.88
I would like to see EXEL buy PPHM for there manufacturing subsidiary AVID, At .55 a share it would be a steal I believe there market cap is 220 million, They will also acquire the rights to Bavituximab which started out as a immunotherapy drug and turned out to be the best Bio Marker out there. Just think of the savings for manufacturing cabo ,plus Avid does 70 million in revenue a year. Just saying.
give us a big hairy g. balls kaboom above 6pct by close